Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 2Genitourinary 2Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1HIV Infections 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Remote Patient Monitoring × Gynecologic × Clear all
NCT03834571 2022-06-21

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

AIDS Malignancy Consortium

Phase 2 Withdrawn
Gynecologic

Uterine Cervical Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡